MIV Therapeutics Licenses Additional Drug-Eluting Coatings

MIV Therapeutics (MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has exercised the option provided in its collaborative research agreement with the University of British Columbia (UBC) to license two additional technologies for advanced biocompatible and drug-eluting coatings for cardiovascular stents and other medical devices.

The announcement of the latest patent licensing comes in the wake of the MIVT's announcement of the licensing of two other technologies from UBC that relate to the use of Hydroxyapatite (HAp) medical device coatings.

All four of these technologies involve applications of HAp, a ceramic material that has demonstrated biocompatibility in a range of research studies, as well as in already-commercialized dental and orthopedic products. The new license will complete MIVT's exclusive rights to advanced methods developed under the collaborative research agreement with UBC for the processing of HAp and its application to implantable medical devices. The patent applications will be filed with the U.S. Patent and Trademark Office.